Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria
The approved dose of pegcetacoplan is predicted to produce rapid and sustained exposure and robust hemoglobin and lactate dehydrogenase responses in adult patients with paroxysmal nocturnal hemoglobinuria, with no initial dose adjustments required for any specific patient population.
Authors
- Ryan L. Crass (ORCID: https://orcid.org/0000-0001-5403-4730)
- Sunny Chapel
- Brandon Smith (ORCID: https://orcid.org/0000-0003-4654-1649)
- Sven Adriaens
- Grant Langdon
Institutions
- Swedish Orphan Biovitrum (Sweden) (SE)
Publication Details
- Journal
- Drugs in R&D
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1007/s40268-024-00500-7
- Citations
- 1
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.24
Funders
- Apellis Pharmaceuticals
- Swedish Orphan Biovitrum